More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Gardiquimod [1020412-43-4]
Chemical Structure
Chemical Structure
Chemical Structure

Gardiquimod [1020412-43-4]

Research Use Only
AG-CR1-3583
AdipoGen Life Sciences
CAS Number1020412-43-4
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight313.4
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Gardiquimod [1020412-43-4]
  • Delivery Days Customer
    10
  • ADR Class
    6.1
  • CAS Number
    1020412-43-4
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Danger,Excepted quantity
  • Molecular Formula
    C17H23N5O
  • Molecular Weight
    313.4
  • Scientific Description
    Chemical. CAS: 1020412-43-4. Formula: C17H23N5O. MW: 313.4. Synthetic. Immune response modifier. Antiviral and antitumor compound Selective ligand for human or mouse Toll-like receptor 7 (TLR7). Induces the activation of NF-kappaB in HEK 293 cells expressing TLR7 at 0.1microg/ml. 10 times more active than Imiquimod (Prod. No. AG-CR1-3569 http://www.adipogen.com/ag-cr1-3569/imiquimod.html ). At high concentrations (3microg/ml) slightly activates TLR8. Shows adjuvant activity to increase the effectiveness of vaccines. - Immune response modifier. Antiviral and antitumor compound Selective ligand for human or mouse Toll-like receptor 7 (TLR7). Induces the activation of NF-kappaB in HEK 293 cells expressing TLR7 at 0.1microg/ml. 10 times more active than Imiquimod (Prod. No. AG-CR1-3569 http://www.adipogen.com/ag-cr1-3569/imiquimod.html ). At high concentrations (3microg/ml) slightly activates TLR8. Shows adjuvant activity to increase the effectiveness of vaccines.
  • SMILES
    CCNCC1=NC2=C(N1CC(C)(C)O)C1=C(C=CC=C1)N=C2N
  • Storage Instruction
    2°C to 8°C,-20°C
  • UN Number
    UN 2811
  • UNSPSC
    12352200

References

  • Double-Stranded RNA Induces an Antiviral Defense Status in Epidermal Keratinocytes through TLR3-, PKR-, and MDA5/RIG-I-Mediated Differential Signaling: B.N. Kalali, et al.; J. Immunol. 181, 2694 (2008)
  • Porcine TLR8 and TLR7 are both activated by a selective TLR7 ligand, imiquimod: J. Zhu, et al.; Mol. Immunol. 45, 3238 (2008)
  • Regioisomerism-dependent TLR7 agonism and antagonism in an imidazoquinoline: N.M. Shukla, et al.; Bioorg. Med. Chem. Lett. 19, 2211 (2009)
  • Intradermal immunization improves protective efficacy of a novel TB vaccine candidate: S.L. Baldwin, et al; Vaccine 27, 3063 (2009)
  • Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells: N.A. Forward, et al.; J. Leukoc. Biol. 87, 117 (2010)
  • The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice: F. Ma, et al.; Cell Mol. Immunol. 7, 381 (2010)
  • TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity: J. Du, et al.; Vaccine 28, 6273 (2010)